Nipocalimab Benefits Hold Up at 2 Years in Teens With Myasthenia Gravis
(MedPage Today) -- Two-year results from the phase III Vibrance-MG study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that the benefits of nipocalimab (Imaavy) were sustained in adolescents...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.